|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We describe two patients with CML and normal karyotype in whom cryptic rearrangements involving chromosomes 9 and 22 resulted in the causative BCR/ABL gene.
|
16337861 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We report a rare cryptic ins(12;9)(p13;q34q34), a chromosomal abnormality involving the ABL1 (9q34) and the ETV6 (alias TEL; 12p13) genes, detectable only by fluorescence in situ hybridization (FISH), in a patient with Philadelphia-negative chronic myeloid leukemia (CML).
|
19480935 |
2009 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The development of BCR/ABL1 tyrosine kinase inhibitors (TKIs) over the past 20 years has dramatically improved the outcomes for patients with every stage of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).
|
26585806 |
2015 |
|
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The quantitation of BCR-ABL1 messenger RNA is requisite for patients with CML, and reverse-transcription real-time quantitative polymerase chain reaction (RQ-PCR) is the method used most extensively in testing laboratories worldwide.
|
28222016 |
2017 |
|
Myeloid Leukemia, Chronic
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Chronic myeloid leukemia (CML) is characterized by the expression of the P210 BCR/ABL fusion protein.
|
14712293 |
2004 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Chronic Myeloid Leukemia (CML) is sustained by a small population of cells with stem cell characteristics known as Leukemic Stem Cells that are positive to BCR-ABL fusion protein, involved with several abnormalities in cell proliferation, expansion, apoptosis and cell cycle regulation.
|
26985855 |
2016 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
This may suggest that the critical event in CML is the formation of a BCR/ABL chimeric gene regardless of its locus in the genome.
|
8697426 |
1996 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Transposition of duplicated chromosomal segment involving fused BCR-ABL gene or ABL oncogene alone in chronic myelocytic leukemia and Ph chromosome-positive acute leukemia with complex karyotypes.
|
10812164 |
2000 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
The BCR/ABL tyrosine kinase has been implicated in the pathogenesis of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL).
|
11264164 |
2001 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we postulate that BCR-ABL1 kinase-mediated inhibition of UNG2 contributes to accumulation of point mutations responsible for TKI resistance causing the disease relapse, and perhaps also other point mutations facilitating malignant progression of CML.
|
23047475 |
2013 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
A 50-year-old female patient with BCR/ABL negative CML and multiple complications of Graves disease, Sweet syndrome, and a fatal pulmonary alveolar proteinosis (PAP) is described in the current study.
|
10931454 |
2000 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
CLINVAR |
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
|
19768693 |
2010 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
This observation prompted us to explore anti-leukemic effects of the combination dasatinib + bosutinib in highly resistant primary CML cells, various CML cell lines (K562, K562R, KU812, KCL22) and Ba/F3 cells harboring various BCR-ABL1 mutant-forms.
|
30711891 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
The use of the tyrosine kinase inhibitor imatinib, which blocks the enzymatic action of the BCR-ABL fusion protein, has represented a critical advance in chronic myeloid leukemia (CML) treatment.
|
16598311 |
2006 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
CLINVAR |
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
|
11423618 |
2001 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.
|
31455852 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
CTD_human |
Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
|
15604220 |
2005 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
|
22005133 |
2012 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Seminested polymerase chain reaction followed by denaturing high-performance liquid chromatography with sequence confirmation were used to detect BCR-ABL1 mutations in 202 CML patients with imatinib resistance at different CML phases.
|
23062378 |
2013 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
The aberrant abl protein product of a chronic myelogenous leukemia (CML) blast crisis cell line (K562) and of five Philadelphia chromosome-positive CML patients in blast crisis were analyzed by an immune complex kinase assay using two antipeptide sera generated against the hydrophilic domain of v-abl and a region within the third exon of the breakpoint cluster region (bcr) respectively.
|
2885048 |
1987 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
CLINVAR |
BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
|
24456693 |
2014 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia.
|
28624216 |
2017 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Bcr-Abl proteins are effective inducers of the leukemic phenotype in chronic myeloid leukemia (CML) and distinct variants of acute lymphoblastic leukemia (ALL).
|
12750174 |
2003 |
|
Myeloid Leukemia, Chronic
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In Philadelphia-positive chronic myeloid leukemia (CML), imatinib resistance frequently emerges because of point mutations in the ABL1 kinase domain, but may also be the consequence of uncontrolled upstream signaling.
|
26072332 |
2015 |
|
Myeloid Leukemia, Chronic
|
0.800 |
Biomarker
|
disease |
BEFREE |
Chronic myeloid leukemia in chronic phase (CML-CP) stem cells (LSCs) produce high levels of mitochondrial ROS, causing oxidative DNA damage, resulting in genomic instability, generating imatinib-resistant BCR-ABL1 kinase mutants and additional chromosomal aberrations.
|
22616753 |
2012 |